1 / 27

Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs

Issues with the statistical analyses in the citizen’s petition for aspirin on reduction of the risk of 1 st MI. Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs Advisory Committee Meeting December 8, 2003. Outline. Background

cybill
Download Presentation

Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Issues with the statistical analyses in the citizen’s petition for aspirin on reduction of the risk of 1st MI Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs Advisory Committee Meeting December 8, 2003

  2. Outline • Background • Sponsor’s ‘meta-analysis’ • HOT study issues • Pooled analysis issues • Exploratory benefit-risk analysis • Summary

  3. Background • The Sponsor requested amendment to the Professional Labeling for aspirin • Indication: Low dose aspirin (75 mg – 325 mg) reduces the risk of a 1st myocardial infarction (MI) in patients with a CHD risk of 10% or greater over 10 years, or there is a positive benefit-risk as assessed by their health care provider • Five studies were selected to support this citizen’s petition

  4. Background • Five studies • (BDT) British Doctor’s Trial (N=5139) • (PHS) Physician’s Health Study (N=22071) • (TPT) Thrombosis Prevention Trial (N=5085) • (HOT) Hypertension Optimal Treatment Study (N=18790) • (PPP) Primary Prevention Project (N=4495) • Total # of subjects = 55580

  5. Background • The agency considered aspirin (BDT and PHS) for this indication before and did not approve it • PHS showed that some patients had a prior MI and aspirin is already known to reduce the risk of recurrent MI • PHS did not achieve statistical significance when all deaths as well as nonfatal MI and stroke were combined • BDT, despite its similarity to PHS, was neutral on the effect of aspirin on MI

  6. Background • What is new in this petition? • Three new studies (TPT, HOT, PPP) were included • HOT (N = 18790) is the largest among the three studies (TPT, N = 5085, PPP, N = 4495) • Sponsor’s ‘Meta-analysis’ of the five studies was submitted to support the petition

  7. Sponsor’s ‘meta-analysis’ Nonfatal MI

  8. Sponsor’s ‘meta-analysis’ Composite of MI, stroke and CV death

  9. Sponsor’s ‘meta-analysis’ Cardiovascular death

  10. The HOT study Silent MI matters • Primary endpoint was major CV events (non-fatal and silent MI, non-fatal stroke, and cardiovascular death) • Silent MIs were obtained by comparing the ECGs at baseline and final visit • n=9399 in aspirin and n=9391 in placebo

  11. The HOT study Silent MI matters • There were 48% and 31% silent MIs in the aspirin group and placebo group, respectively Note: 14% of the patients’ ECGs were not available .

  12. The HOT study Silent MI matters Source: Final report of the HOT study, THE LANCET, 1755-1762, Vol 351, 1998

  13. The HOT study issues • The published paper reported that statistical significance was achieved for the composite endpoint of non-fatal MI, non-fatal stroke, and CV death, and for MI alone. This is misleading • Silent MIs should be included in both efficacy endpoints according to the study protocol • When silent MIs are included, both the primary endpoint (non-fatal & silent MI, non-fatal stroke, and CV death) and MI alone are not statistically significant

  14. Pooled analysis Studies’ summary Source: FDA’s clinical review by Dr. Juan Carlos Pelayo.

  15. Pooled analysis • The patient populations were quite different among the 5 studies (ranging from apparently healthy physicians to patients at high risk of CV disease) • Aspirin doses vary from 75 mg daily to 500 mg daily, including 325 mg every other day

  16. Pooled analysis Primary Efficacy Endpoints Source: FDA’s clinical review by Dr. Juan Carlos Pelayo. NS: Not significant. NA: Not Available

  17. Pooled analysis MI (fatal and nonfatal) (Individual studies) *Silent MIs included. The relative risk, p-value and 95% CI are from Mantel-Haenszel method.

  18. Pooled analysis MI (fatal and nonfatal) *Silent MIs included. #The relative risk, p-value and 95% CI are from Mantel-Haenszel method.

  19. Pooled analysis issues • Some issues associated with the pooled analysis • Why and how the 5 studies were selected • Patient populations are very different among the 5 studies • Aspirin doses are quite different

  20. Overall evidence for MI • MI is only a secondary endpoint in all 5 studies Silent MI is an issue • PHS suggested potential benefit • TPT had a nominal p-value = 0.04 • HOT is not clear • BDT and PPP failed to show statistical significance • The pooled analysis did not provide any additional information beyond those provided by the individual studies

  21. Exploratory benefit-risk analysis • The new indication will expand the risk population • Bleeding is one of the known adverse events for aspirin • Benefit-risk ratios should be considered

  22. Exploratory benefit-risk analysis MI and major bleeding (HOT) Silent MIs included. Multiple Bleeds in the same patient counted only once.

  23. Exploratory benefit-risk analysis Let PT and PS be the probability of MI-free in aspirin group and placebo group, respectively. Let QT and QS be the probability of major bleeding in aspirin group and placebo group, respectively. A possible measure of benefit-risk ratio: R = (PT – PS) / (QT – QS) Ref: Andrew R. Willan etc. Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy. Controlled Clinical Trials 1997; 18:121-130

  24. Exploratory benefit-risk analysis • R measures how many MIs can be prevented at the cost of one major bleeding by using aspirin. CI can be obtained as well • From the HOT study (CIs are wide) Definition of major bleedings can be found in the final report of the HOT study, THE LANCET, 1755-1762, Vol 351, 1998

  25. Exploratory benefit-risk analysis • Overall, 54 MIs may be prevented at the cost of 100 major bleeds by using aspirin • For male, 85 MIs may be prevented at the cost of 100 major bleeds by using aspirin • For female, 14 MIs may be prevented at the cost of 100 major bleeds by using aspirin

  26. Summary • MI is only a secondary endpoint in all 5 studies. Silent MI is an issue • For primary prevention of MI, • PHS suggested potential benefit • TPT had a nominal p-value = 0.04 • HOT failed to show statistical significance when silent MIs were included (protocol specified) • BDT failed to show statistical significance • PPP failed to show statistical significance

  27. Summary • Some issues with the pooled analysis • Studies selection (how and why) • Risk factor of the patient population • Aspirin doses • The pooled analysis does not provide any additional information beyond those provided by the individual studies • The benefit and risk should be considered

More Related